MAIA Biotechnology, Inc. (NYSE American: MAIA), a pioneering company focused on developing immunotherapies targeting telomeres for cancer treatment, has confirmed its participation in the prestigious BIO International Convention scheduled from June 3 to June 6, 2024, in San Diego, California. Recognized as the premier gathering for the biotechnology industry, this event attracts over 20,000 global leaders in the biotech sector. Dr. Vlad Vitoc, Chairman and CEO of MAIA, will present the latest insights from the company’s Phase 2 THIO-101 clinical trial during the convention. This trial assesses ..read more

RVL Pharmaceuticals has proudly announced that Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, its prescription eye drop, has received the esteemed 2024 Shape Skin Award from Shape Magazine. This prestigious recognition, naming Upneeq® as “Best for Lift” in the professional category, marks the third consecutive year of acknowledgment for the product by Shape. Previously, Upneeq® was honored as “Best Professional Grade” in 2022 and received the 2023 Shape Beauty Award for “Best In-Office” treatments. Upneeq® is FDA approved for treating acquired ptosis (droopy eyelids) in adult ..read more

Kirby McInerney LLP is reminding investors of the upcoming May 28, 2024 deadline to seek lead plaintiff status in a federal securities class action related to bluebird bio, Inc. (NASDAQ: BLUE). The lawsuit concerns securities acquired during April 24, 2023, through December 8, 2023 (the “Class Period”). During this period, Bluebird Bio announced FDA approval of its drug Lyfgenia (lovo-cel) for treating sickle cell disease in patients aged 12 and above with a history of vaso-occlusive events. However, the approval came with a black box warning after two patients developed AML during clinical tr ..read more

Guardant Health, Inc. (Nasdaq: GH), a prominent player in precision oncology, disclosed today that its Compensation Committee, on April 22, 2024, sanctioned the allocation of restricted stock units (“RSUs”) corresponding to 215,601 shares of its common stock for 94 newly appointed non-executive staff, and non-qualified stock option awards enabling the purchase of a total of 98,076 shares of its common stock for three new non-executive employees. These grants were effective as of May 13, 2024, under the Guardant Health, Inc., 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan ..read more

The leading developer in thermal energy storage (“TES”) globally, Brenmiller, announced significant expansion in its project pipeline, marking a record level for the Company. As of May 1, 2024, Brenmiller boasts a project pipeline comprising 49 potential contracts at various stages of development for its bGen™ ZERO TES systems, valued at over $500 million. These projects represent more than 6,000 MWh of zero-emission heat. Spanning 12 industries, Brenmiller is advancing potential projects across 13 countries, including the U.S., Spain, Hungary, Israel, and India. Of the pipeline projects, appr ..read more

Today, ImmunityBio has announced the release of three podcasts in collaboration with UroToday, shedding light on the recent FDA approval of ANKTIVA® (N-803, also known as nogapendekin alfa inbakicept-pmln) alongside Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) and advancements in bladder cancer research. Dr. Patrick Soon-Shiong, the Executive Chairman and Global Chief Scientific Officer at ImmunityBio, delved into the breaking news of ANKTIVA’s FDA approval with Dr. Ashish Kamat, an Endowed Professor of Urologic Oncology and Cancer Resea ..read more

NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have forged a robust strategic alliance aimed at shaping the future landscape of global health and wellness. Drawing upon their respective proficiencies and groundbreaking research in coenzymes and NAD+, both entities are united in their vision to pioneer advanced NAD-based therapeutics and supplements, catering to those aspiring for enhanced longevity, vitality, and well-being. The formalization of this collaboration occurred on May 6, 2024, marked by the signing of a partnership cooperation agreement between Bontac Bio-Engineerin ..read more

Aiming to advance treatment options for seizure disorders, Marinus Pharmaceuticals has successfully completed enrollment in the global Phase 3 TrustTSC trial. This trial assesses oral ganaxolone’s efficacy in managing seizures associated with tuberous sclerosis complex (TSC) across various age groups. Dr. Alex Aimetti, Marinus Pharmaceuticals’ Chief Scientific Officer, expressed gratitude to the TSC community for their support and participation in this pivotal trial. Dr. Joseph Hulihan, Marinus’ Chief Medical Officer, highlighted modifications made to ganaxolone’s titration schedule based on i ..read more

Azitra, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering innovative therapies for precision dermatology, has unveiled preclinical findings from its cutting-edge platform and pipeline. These findings are being presented at the Society of Investigative Dermatology (SID) 2024 Annual Meeting in Dallas, TX, on Friday, May 17, 2024, in two oral sessions titled “Staphylococcus epidermidis for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity” and “Cutaneous delivery of LEKTI via an engineered strain of Staphylococcus epidermidis ..read more

The World Health Organization (WHO) has unveiled its updated Bacterial Priority Pathogens List (BPPL) for 2024, highlighting 15 families of antibiotic-resistant bacteria grouped into critical, high, and medium categories for prioritization. This list serves as a compass for the development of crucial treatments aimed at curbing the spread of antimicrobial resistance (AMR). AMR occurs when microorganisms like bacteria, viruses, fungi, and parasites become unresponsive to medications, leading to exacerbated illnesses, heightened disease transmission, and increased mortality rates. The misuse and ..read more